Seelos Therapeutics Stock Earnings Per Share
| SEEL Stock | USD 0.39 0.11 22.00% |
Seelos Therapeutics fundamentals help investors to digest information that contributes to Seelos Therapeutics' financial success or failures. It also enables traders to predict the movement of Seelos OTC Stock. The fundamental analysis module provides a way to measure Seelos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seelos Therapeutics otc stock.
Seelos |
Seelos Therapeutics OTC Stock Earnings Per Share Analysis
Seelos Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Seelos Therapeutics Earnings Per Share | 351.04 X |
Most of Seelos Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seelos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Seelos Therapeutics has an Earnings Per Share of 351 times. This is much higher than that of the Pharmaceuticals sector and notably lower than that of the Health Care industry. The earnings per share for all United States stocks is notably lower than that of the firm.
Seelos Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seelos Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Seelos Therapeutics could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics of similar companies.Seelos Therapeutics is currently under evaluation in earnings per share category among its peers.
Seelos Fundamentals
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Shares Owned By Insiders | 0.49 % | |||
| Shares Owned By Institutions | 4.46 % | |||
| Number Of Shares Shorted | 170.89 K | |||
| Price To Book | 15.10 X | |||
| Price To Sales | 0.37 X | |||
| Revenue | 2.2 M | |||
| Gross Profit | (46.65 M) | |||
| EBITDA | (40.44 M) | |||
| Net Income | (37.88 M) | |||
| Cash And Equivalents | 41.25 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 14.23 M | |||
| Debt To Equity | 0.73 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | (135.50) X | |||
| Cash Flow From Operations | (23.91 M) | |||
| Short Ratio | 0.14 X | |||
| Earnings Per Share | 351.04 X | |||
| Target Price | 120.0 | |||
| Beta | 1.85 | |||
| Market Capitalization | 743.68 K | |||
| Total Asset | 5.42 M | |||
| Retained Earnings | (252.63 M) | |||
| Working Capital | (33.52 M) | |||
| Net Asset | 5.42 M |
About Seelos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Seelos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Seelos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Seelos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Seelos OTC Stock
Seelos Therapeutics financial ratios help investors to determine whether Seelos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Seelos with respect to the benefits of owning Seelos Therapeutics security.